New number of shares and votes in Moberg Pharma AB (publ)

New number of shares and votes in Moberg Pharma AB (publ)

STOCKHOLM, January 29^th 2021. During January 2021, the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) (“Moberg Pharma” or the “Company”) has increased due to the completion of the previously announced rights issue, and the final conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.

During January 2021, the total number of shares and votes in the Company has increased by 24,181,899, corresponding to 24,181,899 votes, whereof 23,175,576 common shares through the registration of the rights issue and 1,006,323 shares as a result of the board of directors’ resolution to approve Nice & Green S.A.’s request to convert convertible notes into common shares of the Company. As a result of the completion of the rights issue, the financing agreement regarding convertible notes is terminated.

At the date of this press release, the total number of shares in Moberg Pharma amounts to 44,601,425. All shares are common shares. The total number of votes are 44,601,425. At the date of this press release, the Company holds 554,746 own common shares.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, telephone: +46 76 - 805 82 88, e-mail: mark.beveridge@mobergpharma.se

About this information
The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on January 29^th 2021 at 8:00 am CET.

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis, intended to be spun off in the separate company OncoZenge. Clinical data generated for both assets indicate that they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).